In yesterday’s Wall Street session, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) shares traded at $10.47, up 2.45% from the previous session.
As of this writing, 4 analysts cover Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $9.00, we find $13.00. Given the previous closing price of $10.22, this indicates a potential upside of 27.2 percent. IRWD stock price is now -0.98% away from the 50-day moving average and -5.88% away from the 200-day moving average. The market capitalization of the company currently stands at $1.59B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
There are 2 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $12.75 as their price target over the next twelve months.
.
In other news, MCCOURT Thomas A, Chief Executive Officer sold 21,148 shares of the company’s stock on May 08. The stock was sold for $224,592 at an average price of $10.62. Upon completion of the transaction, the Chief Executive Officer now directly owns 820,916 shares in the company, valued at $8.59 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 27, Chief Executive Officer MCCOURT Thomas A sold 46,129 shares of the business’s stock. A total of $492,196 was realized by selling the stock at an average price of $10.67. This leaves the insider owning 842,064 shares of the company worth $8.82 million. Insiders disposed of 834,307 shares of company stock worth roughly $8.74 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IRWD stock. A new stake in Ironwood Pharmaceuticals Inc. shares was purchased by BALYASNY ASSET MANAGEMENT L.P. during the first quarter worth $9,954,000. BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC invested $2,660,000 in shares of IRWD during the first quarter. In the first quarter, TWINBEECH CAPITAL LP acquired a new stake in Ironwood Pharmaceuticals Inc. valued at approximately $2,093,000. EXCHANGE TRADED CONCEPTS, LLC acquired a new stake in IRWD for approximately $1,718,000. SQUAREPOINT OPS LLC purchased a new stake in IRWD valued at around $1,600,000 in the second quarter. In total, there are 361 active investors with 112.77% ownership of the company’s stock.
Friday morning saw Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) opened at $10.23. During the past 12 months, Ironwood Pharmaceuticals Inc. has had a low of $9.73 and a high of $12.66. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 36.30, and a quick ratio of 36.30. The fifty day moving average price for IRWD is $10.57 and a two-hundred day moving average price translates $11.12 for the stock.
The latest earnings results from Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.25, beating analysts’ expectations of $0.24 by 0.01. This compares to $0.20 EPS in the same period last year. The net profit margin was 43.60% and return on equity was 29.30% for IRWD. The company reported revenue of $104.06 million for the quarter, compared to $97.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.7 percent. For the current quarter, analysts expect IRWD to generate $103.29M in revenue.
Ironwood Pharmaceuticals Inc.(IRWD) Company Profile
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
